Abstract: Page 1 of 21 COVID-19 oral antivirals and hospitalisation Yip, et al. iew ed Impact of the use of oral antiviral agents on the risk of hospitalisation in community COVID-19 patients Running title: COVID-19 oral antivirals and hospitalisation risk in community Terry Cheuk-Fung Yip*1,2,3, Grace Chung-Yan Lui*1,2,4, Mandy Sze-Man Lai1,2, Vincent WaiSun Wong 1,2,3, Yee-Kit Tse1,2,3, Bosco Hon-Ming Ma1, Elsie Hui1, Maria KW Leung6, Henry ev Lik-Yuen Chan2,5,7, David Shu-Cheong Hui1,2,4, Grace Lai-Hung Wong1,2,3 1Department of Medicine and Therapeutics, 2Medical Data Analytics Centre (MDAC), 3Institute er r of Digestive Disease, 4Stanley Ho Centre for Emerging Infectious Diseases, Jockey Club School of Public Health & Primary Care, and Faculty of Medicine5, The Chinese University of Hong Kong; Hong Kong pe 6Department of Family Medicine, Prince of Wales Hospital, Hospital Authority, Hong Kong 7Department of Internal Medicine, Union Hospital, Hong Kong *TCF Yip and GCY Lui contributed equally to this study. ot Keywords: SARS-CoV-2, hospital admission, death, molnupiravir, nirmatrelvir/ritonavir Abbreviations: CDARS = Clinical Data Analysis and Reporting System, CI = confidence tn interval, DM = diabetes mellitus, ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification, IMV = invasive mechanical ventilation, HR = hazard ratio, ICU rin = intensive care unit, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. 300 Text word count: 3,441 No. of tables: 3 No. of figures: 2 ep Summary word count: Co-correspondence: Pr 1. Grace Lai-Hung Wong, MBChB(Hons, CUHK), MD(CUHK), FRCP(Lond, Edin), FHKCP, FHKAM(Medicine) 1 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4112160 Page 2 of 21 COVID-19 oral antivirals and hospitalisation Yip, et al. iew ed 2. David Shu-Cheong Hui, MBBS (UNSW); MD(UNSW); FRACP; FRCP (Lond, Glasg, Edin); FHKCP; FHKAM(Medicine) Department of Medicine and Therapeutics, 9/F Prince of Wales Hospital, Shatin, Hong Kong. Telephone: 852-2632-3538, Fax:852-2637-3852, Email: wonglaihung@cuhk.edu.hk Declaration of Interests ev Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Grace Lui has served as an advisory committee member for Gilead, Merck and GSK, speaker for er r Merck and Gilead, and received research grant from Gilead, Merck and GSK. Vincent Wong has served as a consultant or advisory committee member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, pe Pfizer, ProSciento, Sagimet Biosciences and TARGET PharmaSolutions; and a speaker for Abbott, AbbVie, Echosens, Gilead Sciences and Novo Nordisk. He has received a research grant from Gilead Sciences, and is a cofounder of Illuminatio Medical Technology Limited. ot Henry Chan has served as an Independent Non-Executive Director for Shanghai Henlius Biotech Inc; as an advisory board member for Aligos, Aptorum, Arbutus, Hepion, Janssen, Gilead, tn Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics, and Vir Biotechnology; and as a speaker for Gilead, Roche, and Viatris. rin Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, and as a speaker for Abbott, Abbvie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, ep Janssen and Roche. She has also received a research grant from Gilead..